Chimerix (CMRX) Misses Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Chimerix Announces Fourth Quarter and Full Year 2015 Financial Results
February 29, 2016 7:30 AM EST- Company to hold conference call at 8:30am ET today -- Survival and other key data from AdVise and matched controls to be reviewed with regulators in Summer 2016 -
DURHAM, N.C., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ: CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today reported financial results for the fourth quarter and full year ended December 31, 2015.Â
The Company also provided a strategic update on expected 2016 milestones and corporate highlights, including:
... More